查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023年至2028年大肠筛检市场预测
市场调查报告书
商品编码
1410051

2023年至2028年大肠筛检市场预测

Colorectal Cancer Screening Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021年大肠筛检市场规模为16.39亿美元，预估预测期间内复合年增长率为5.55%。

随着老龄化的增长，结肠和直肠内壁上形成的称为息肉的非癌性生长物是大肠最常发生的地方。由于生活方式的改变、糖尿病和肥胖，大肠盛行率不断上升，这是大肠筛检市场的主要成长动力。此外，人口中吸烟文化的增加以及老年人口的增加预计也会增加大肠的风险并推动大肠肠癌筛检市场。人们对大肠负面影响的认识不断提高，市场参与企业透过推出产品来提高可及性，预计将进一步扩大大肠筛检市场。

大肠盛行率上升

大肠直肠癌患者数量的增加表明了筛检的需求，这对大肠筛检市场做出了积极贡献。据世界卫生组织称，2020 年，大肠确诊病例超过 190 万例，成为全球第三大常见癌症类型。据美国癌症协会称，在美国，预计 2023 年将确诊 153,020 例大肠(CRC) 新病例，导致 52,550 人死亡。

改变你的生活方式和饮食习惯

典型的西方饮食脂肪和热量高，膳食纤维含量低，可能与大肠癌有关，而大肠癌更容易发生在不运动的人身上。根据 NCBI 的数据，美国成年人平均每天坐着的时间为 7.7 小时，韩国成年人为 8.3 小时。据世界卫生组织称，世界上超过80%的年轻人没有得到足够的锻炼，导致许多严重的健康问题，包括大肠。因此，久坐生活方式的采用有望培育大肠​​筛检市场。

吸烟人口增加

大肠直肠癌（CRC）的一个重要危险因子是吸烟。 NCBI 研究发现，吸烟会显着增加动物模型中结直肠癌形成的风险以及人类大肠直肠癌的发病率和死亡率。根据世界卫生组织统计，2020年，全球有36.7%的男性和7.8%的女性消费烟草，占全球人口的22.3%。根据英国癌症研究中心的数据，在英国，2021 年有 690 万名成年吸烟者，占成年人（18 岁及以上）的 13.3%。如此庞大的吸烟人口预示着大肠病例数将很快增加，大肠筛检市场也将扩大。

人口老化与慢性发炎疾病

大多数大肠直肠癌发生在 50 岁以上的人群中。根据梅奥诊所的一份报告，50 岁以下人群的结肠癌发生率正在增加。根据美国癌症协会统计，147,950 例大肠病例中有 80,010 例为 65 岁及以上。因此，老年人口的增加预计将加强大肠筛检市场。例如，根据世界卫生组织估计，60岁及以上人口预计将从2020年的10亿增加到2030年的14亿。

提高对大肠直肠癌的认识

旨在提高人们认识的多项宣传活动加上技术创新正在积极推动大肠筛检市场。例如，在美国，作为 CDC 生命筛检计画的一部分，正在对 45 岁及以上的人群进行定期大肠筛检的价值的教育。作为全国大肠癌行动运动的一部分，我们正在对 45 岁及以上的人群进行有关定期大肠筛检的价值的教育。此外，2023年4月，国际癌症研究机构发布了关于五大洲癌症筛检的Can5倡议的第一份报告。

北美地区预计将大幅成长

预计北美地区在预测期内将占据大肠筛检市场的重要份额。造成这一比例的因素包括受过高等教育的人口、政府计划以及导致大肠疾病的高盛行率，例如吸烟和久坐的生活方式。例如，根据CDC的资料，约有1,600名18岁以下的美国青少年每天第一次点烟，另有1,600万人患有因吸烟引起的严重疾病。此外，Exact Science Corporation 和 Polymedco Inc. 等主要市场领导的出现预计将进一步推动大肠筛检市场的发展。

市场主要发展

2023 年 3 月，CDC 与 CPCRN 和 NACCD 合作，宣布推出提高乳癌、子宫颈癌和大肠筛检品质的工具。该计划旨在支持社区努力提高癌症筛检率并挽救更多生命。 2023 年 2 月，Sanora Quest Labs 推出了该公司首款大肠家庭筛检套件InSure ONE。将检查粪便样本中的人体血红蛋白，以检查是否有下消化道出血，这是大肠的症状。 2022 年 5 月，Guardant Health 宣布推出 Shield Test，可透过短时间抽血检测大肠。此测试不需要时间、麻醉、特殊准备或用餐调整。识别血液中 CRC 讯号的早期迹象。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 调查过程

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章大肠筛检市场：通过筛检测试

  • 介绍
  • 乙状结肠镜检查
  • 粪便测试
  • CT大肠造影
  • 大肠镜检查
  • 其他的

第六章大肠筛检市场：依最终用户分类

  • 介绍
  • 独立诊断实验室
  • 医院
  • 其他的

第七章大肠筛检市场：依地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第九章 公司简介

  • Eiken Chemical Co. Ltd
  • Epigenomics Inc.
  • Exact Sciences Corporation
  • Polymedco Inc
  • F. Hoffmann-La Roche AG
  • QuidelOrtho Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Olympus Corporation
简介目录
Product Code: KSI061615704

The colorectal cancer screening market was valued at US$1.639 billion in 2021 and is expected to grow at a CAGR of 5.55% during the forecast period.

The noncancerous growth known as a polyp, which can appear on the inner wall of the colon or rectum as people age, is where colorectal cancer most frequently develops. The higher prevalence rate of colorectal cancer due to changing lifestyles, diabetes, and obesity are major growth drivers of the colorectal cancer screening market. Moreover, the increasing smoking culture among people coupled with the growing older population is also expected to increase the risk of colon cancer thereby propelling the colorectal cancer screening market. The increasing awareness about the adverse effects of colorectal cancer and product launches by the market players resulting in more accessibility are further contemplated to augment the colorectal cancer screening market.

Higher Prevalence of Colorectal Cancer

The rising colorectal cancer cases indicate the need for screening and thus contribute positively to the colorectal cancer screening market. With more than 1.9 million cases identified, colorectal cancer was the third most frequent cancer type in the world in 2020, according to the WHO. A projected 153,020 new cases of colorectal cancer (CRC) will be identified in the US in 2023, and 52,550 deaths are estimated as per the American Cancer Society.

Changing Lifestyle and Diet

A normal Western diet that is high in fat and calories and poor in fiber may be linked to colon and rectal cancer and Colon cancer is more prone to occur in those who are inactive. According to NCBI, the average amount of time spent sitting each day is 7.7 hours for adults in America and 8.3 hours for the Korean population. According to the WHO, over 80% of young people worldwide don't participate in enough physical activity leading to numerous serious health issues including colorectal cancer. Therefore, the adoption of a sedentary lifestyle is expected to aid the colorectal cancer screening market.

Growing Prevalence of Smoking among Population

A significant risk factor for colorectal cancer (CRC) is cigarette smoking. Smoking was found to dramatically increase the risk of CRC formation in animal models as well as CRC incidence and mortality in humans, according to studies by the NCBI. According to the WHO, 36.7% of all males and 7.8% of all women consumed tobacco worldwide in 2020, making up 22.3% of the global population. In the UK, there were 6.9 million adult smokers in 2021 equating to 13.3% of adults (aged 18+) according to Cancer Research UK. This huge population engaged in smoking and tobacco indicates higher cases of colorectal cancer cases shortly thus widening the colorectal cancer screening market.

Rising Older Population and Chronic Inflammatory Diseases

The majority of instances affect persons over 50 years of age. The Mayo Clinic reports that colon cancer rates among persons under 50 have been rising. According to the American Cancer Society, 80,010 out of a total of 147,950 colorectal cancer cases were reported in individuals aged 65 years or above i.e., around 50% of total cases. The rising older population is therefore contemplated to bolster the colorectal cancer screening market. For instance, people aged 60 years or above are projected to reach 1.4 billion by 2030 from 1 billion in 2020 according to the WHO estimates.

Increased Awareness about Colorectal Cancer

Multiple campaigns to increase awareness among people coupled with technological innovation are positively driving the colorectal cancer screening market. For instance, US people aged 45 years or older are educated about the value of routine colorectal cancer screenings as part of the CDC's Screen for Life: National Colorectal Cancer Action Campaign. Moreover, in April 2023, the International Agency for Cancer Research published an inaugural report under its Can5 initiative on cancer screening in five continents.

North America is Expected to Grow Significantly

The North American region is expected to hold a significant share of the colorectal cancer screening market during the forecast period. Various factors attributed to such a share are an educated population, government programs, and a higher prevalence of colorectal-causing factors such as smoking and a sedentary lifestyle. For instance, Around 1,600 American teenagers under the age of 18 light up their first cigarette every day, and 16 million additional people suffer from a serious ailment brought on by smoking as per the CDC data. Moreover, the presence of major market leaders such as Exact Science Corporation, and Polymedco Inc. are further expected to aid the colorectal cancer screening market.

Major Market Players

  • Exact Science Corporation is a US-based molecular diagnostics company that specializes in detection of early-stage cancers. Cologuard is a stool DNA-bases colorectal cancer screening test offered by the company and it is also developing a blood-based screening method for colorectal cancer.
  • Eiken Chemical Co. Ltd. is one of the leading clinical testing companies. The company launched a fully automated fecal immunochemical test OC-SENSOR Ceres™ in November 2022.

Key Market Developments

  • In March 2023, in association with CPCRN and NACCD, the CDC introduced a tool for improving the quality of cancer screening for breast, cervical, and colorectal cancers. This package intends to assist community initiatives to boost cancer screening rates and enhance the number of lives saved.
  • In February 2023, Sanora Quest Labs introduced InSure ONE, its first colorectal cancer home screening kit. In fecal samples, it looks for human hemoglobin to check for lower gastrointestinal bleeding, which could be a symptom of colon cancer.
  • In May 2022, with just a quick blood draw, Guardant Health introduced the Shield test for colorectal cancer. It doesn't require any more time, anesthesia, specific preparation, or dietary adjustments. It recognizes early indications of CRC signals in the blood.

Segmentation:

By Screening Test

  • Flexible Sigmoidoscopy
  • Stool-based Tests
  • CT Colonography
  • Colonoscopy
  • Others

By End-User

  • Independent Diagnostic Labs
  • Hospitals
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. COLORECTAL CANCER SCREENING MARKET, BY SCREENING TEST

  • 5.1. Introduction
  • 5.2. Flexible Sigmoidoscopy
  • 5.3. Stool-based Tests
  • 5.4. CT Colonography
  • 5.5. Colonoscopy
  • 5.6. Others

6. COLORECTAL CANCER SCREENING MARKET, BY END USERS

  • 6.1. Introduction
  • 6.2. Independent Diagnostic Labs
  • 6.3. Hospitals
  • 6.4. Others

7. COLORECTAL CANCER SCREENING MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. The Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Israel
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations

9. COMPANY PROFILES

  • 9.1. Eiken Chemical Co. Ltd
  • 9.2. Epigenomics Inc.
  • 9.3. Exact Sciences Corporation
  • 9.4. Polymedco Inc
  • 9.5. F. Hoffmann-La Roche AG
  • 9.6. QuidelOrtho Corporation
  • 9.7. Siemens Healthineers AG
  • 9.8. Sysmex Corporation
  • 9.9. Olympus Corporation